Description

Larotaxel is a semi-synthetic taxane derivative developed as a potent antineoplastic agent. This compound is significant for its mechanism of action, which involves stabilizing microtubules to inhibit cell division, offering a targeted approach in oncology research and development. It is primarily needed by pharmaceutical R&D departments, contract research organizations (CROs), and academic institutions engaged in the discovery and synthesis of next-generation chemotherapeutic agents. Larotaxel CAS NO 156294-36-9 represents a critical intermediate and reference standard for advancing cancer therapeutics.

Application

• Pharmaceutical Active Pharmaceutical Ingredient (API): Serves as the core active component in the formulation of investigational anti-cancer drugs.
• Oncology Research & Development: Used as a key reference standard and intermediate in preclinical and clinical studies targeting various solid tumors.
• Mechanistic Studies: Employed in biochemical assays to study microtubule dynamics, apoptosis, and drug resistance mechanisms.
• Analytical Reference Standard: Essential for quality control and method development in analytical laboratories (HPLC, LC-MS) for drug quantification and impurity profiling.
• Synthetic Chemistry: Acts as a sophisticated building block for the semi-synthesis of novel taxane analogs with potentially improved efficacy or safety profiles.
• Drug Delivery System Development: Investigated for incorporation into advanced delivery platforms like nanoparticles or liposomes to enhance bioavailability and targeting.

Basic Information

Product Name	Larotaxel
CAS No.	156294-36-9
Molecular Formula	C45H53NO14
Molecular Weight	831.91 g/mol
Synonyms	RPR 109881A; XRP9881; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-Acetoxy-9-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate; Larotaxel Dihydrate; Larotaxel (anhydrous)
EINECS	Contact for details

Quality Control

Our Larotaxel is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing to ensure identity, purity, and consistency, aligning with ICH guidelines for pharmaceutical intermediates. Comprehensive testing includes HPLC for assay and related substances, residual solvent analysis, and specific identification tests. A Certificate of Analysis (COA) detailing all specifications and results is provided with every shipment to support your regulatory and research requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider desiccants or inert atmosphere conditions.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Water Content (KF)	≤ 2.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.